53 research outputs found

    Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis

    Get PDF
    Anti-tumor necrosis factor alpha (anti-TNF) biologic therapy is a widely used treatment for rheumatoid arthritis (RA). It is unknown why some RA patients fail to respond adequately to anti-TNF therapy, which limits the development of clinical biomarkers to predict response or new drugs to target refractory cases. To understand the biological basis of response to anti-TNF therapy, we conducted a genome-wide association study (GWAS) meta-analysis of more than 2 million common variants in 2,706 RA patients from 13 different collections. Patients were treated with one of three anti-TNF medications: etanercept (n = 733), infliximab (n = 894), or adalimumab (n = 1,071). We identified a SNP (rs6427528) at the 1q23 locus that was associated with change in disease activity score (ΔDAS) in the etanercept subset of patients (P = 8×10-8), but not in the infliximab or adalimumab subsets (P>0.05). The SNP is predicted to disrupt transcription factor binding site motifs in the 3â€Č UTR of an immune-related gene, CD84, and the allele associated with better response to etanercept was associated with higher CD84 gene expression in peripheral blood mononuclear cells (P = 1×10-11 in 228 non-RA patients and P = 0.004 in 132 RA patients). Consistent with the genetic findings, higher CD84 gene expression correlated with lower cross-sectional DAS (P = 0.02, n = 210) and showed a non-significant trend for better ΔDAS in a subset of RA patients with gene expression data (n = 31, etanercept-treated). A small, multi-ethnic replication showed a non-significant trend towards an association among etanercept-treated RA patients of Portuguese ancestry (n = 139, P = 0.4), but no association among patients of Japanese ancestry (n = 151, P = 0.8). Our study demonstrates that an allele associated with response to etanercept therapy is also associated with CD84 gene expression, and further that CD84 expression correlates with disease activity. These findings support a model in which CD84 genotypes and/or expression may serve as a useful biomarker for response to etanercept treatment in RA patients of European ancestry. © 2013 Cui et al

    Extreme Evolutionary Disparities Seen in Positive Selection across Seven Complex Diseases

    Get PDF
    Positive selection is known to occur when the environment that an organism inhabits is suddenly altered, as is the case across recent human history. Genome-wide association studies (GWASs) have successfully illuminated disease-associated variation. However, whether human evolution is heading towards or away from disease susceptibility in general remains an open question. The genetic-basis of common complex disease may partially be caused by positive selection events, which simultaneously increased fitness and susceptibility to disease. We analyze seven diseases studied by the Wellcome Trust Case Control Consortium to compare evidence for selection at every locus associated with disease. We take a large set of the most strongly associated SNPs in each GWA study in order to capture more hidden associations at the cost of introducing false positives into our analysis. We then search for signs of positive selection in this inclusive set of SNPs. There are striking differences between the seven studied diseases. We find alleles increasing susceptibility to Type 1 Diabetes (T1D), Rheumatoid Arthritis (RA), and Crohn's Disease (CD) underwent recent positive selection. There is more selection in alleles increasing, rather than decreasing, susceptibility to T1D. In the 80 SNPs most associated with T1D (p-value <7.01×10−5) showing strong signs of positive selection, 58 alleles associated with disease susceptibility show signs of positive selection, while only 22 associated with disease protection show signs of positive selection. Alleles increasing susceptibility to RA are under selection as well. In contrast, selection in SNPs associated with CD favors protective alleles. These results inform the current understanding of disease etiology, shed light on potential benefits associated with the genetic-basis of disease, and aid in the efforts to identify causal genetic factors underlying complex disease

    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

    Get PDF
    Objectives: To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for the most recent developments in the field. Methods: An international task force considered new evidence supporting or contradicting previous recommendations and novel therapies and strategic insights based on two systematic literature searches on efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) since the last update (2016) until 2019. A predefined voting process was applied, current levels of evidence and strengths of recommendation were assigned and participants ultimately voted independently on their level of agreement with each of the items. Results: The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering on sustained clinical remission is provided. Cost and sequencing of b/tsDMARDs are addressed. Initially, MTX plus GCs and upon insufficient response to this therapy within 3 to 6 months, stratification according to risk factors is recommended. With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD or JAK inhibitor should be added to the csDMARD. If this fails, any other bDMARD (from another or the same class) or tsDMARD is recommended. On sustained remission, DMARDs may be tapered, but not be stopped. Levels of evidence and levels of agreement were mostly high. Conclusions: These updated EULAR recommendations provide consensus on the management of RA with respect to benefit, safety, preferences and cost

    Statistics and Data Analysis for Social Workers

    No full text
    160 p.; 21 cm

    Fladdermöss i Östergötland : Resultat frĂ„n inventeringar utförda 1978-2004

    No full text
    denna rapport redovisas resultat frĂ„n olika fladdermusinventeringar som utförts i Östergötland under Ă„ren1978-2004. FrĂ„n 1994 och framĂ„t har det genomförts en mer systematisk inventering av fladdermöss. Undersenare Ă„r har inventeringen skett inom ramen för den inventeringsverksamhet som LĂ€nsstyrelsen ÖstergötlandpĂ„började 1993 under benĂ€mningen Projekt hotade arter. Projektet Ă€r ett samarbete mellan lokala, regionala ochcentrala myndigheter och organisationer. Syftet med projektet Ă€r att öka kunskapen om de rödlistade arternasutbredning, liksom att erhĂ„lla ett bĂ€ttre underlag för naturvĂ„rdsarbetet i lĂ€net. Fladdermössen utgör hĂ€r en viktigoch intressant del av faunan i kulturlandskapet, dĂ„ rik artförekomst av fladdermöss indikerar miljöer med storbiologisk mĂ„ngfald. 213 lokaler har hittills inventerats. Gemensamt för flertalet av de 13 artrikaste lokalerna, med sju till nio arter, Ă€ratt det Ă€r heterogena miljöer bestĂ„ende av trĂ€dbĂ€rande betesmarker med gamla, ihĂ„liga trĂ€d i ett gammalt odlingslandskap,oftast i nĂ€rhet till vatten och med anknytning till större gĂ„rdar eller gods rika pĂ„ gamla byggnader. Av de 16 arter som regelbundet finns i landet har 11 pĂ„trĂ€ffats i Östergötland. Av landets sex rödlistade arterförekommer fyra i lĂ€net. Dessa Ă€r barbastell, Barbastella barbastellus (EN), fransfladdermus, Myotis nattereri (VU),mustaschfladdermus, Myotis mystacinus (VU) och trollfladdermus, Pipistrellus nathusii (NT). Fyndlokalerna förbarbastell Ă€r, med ett undantag, koncentrerade till den allra sydligaste delen av lĂ€net. Fransfladdermusen har pĂ„trĂ€ffatsföretrĂ€desvis pĂ„ artrika lokaler. 84 % av fynden har gjort pĂ„ lokaler med fem till nio arter. PĂ„ tvĂ„ lokaler ilĂ€net har mustaschfladdermus konstaterats med hjĂ€lp av fĂ„ngst. Under 2004 pĂ„trĂ€ffades för första gĂ„ngen trollfladdermuspĂ„ en lokal i norra delen av lĂ€net. Stor fladdermus var tidigare bĂ„de internationellt och nationelltrödlistad, men har tagits bort frĂ„n listorna pĂ„ grund av nya kriterier frĂ„n den internationella naturvĂ„rdsunionenIUCN. Arten har ocksĂ„ strukits frĂ„n listan över regionalt hotade arter. För en fortsatt kunskapsuppbyggnad pĂ„ omrĂ„det Ă€r det angelĂ€get att utveckla metodiken sĂ„ att svĂ„rdetekteradearter lĂ€ttare kan hittas. För att fĂ„ klarlagt huruvida fransfladdermus kan betraktas som en indikatorart för artrikamiljöer eller ej bör artrika lokaler dĂ€r arten Ă€nnu ej pĂ„trĂ€ffats Ă„terinventeras, liksom Ă€ven artfattigare lokaler dĂ€r ejbelagda indikationer om artens förekomst finns

    Statistic and data analysis for social workers

    No full text
    160 p.; 23 cm

    Extreme weather affects colonization : extinction dynamics and the persistence of a threatened butterfly

    No full text
    Extreme weather events can be expected to increase in frequency in the future. Our knowledge on how this may affect species persistence is, however, very limited. For reliable projections of future persistence we need to understand how extreme weather affects species' population dynamics.We analysed the effect of extreme droughts on the host plant Succisa pratensis, colonization-extinction dynamics, and future persistence of the threatened marsh fritillary Euphydryas aurinia. Specifically, we studied a metapopulation inhabiting a network of 256 patches on Gotland (Sweden), where the summer of 2018 was the driest ever recorded. We analysed how the frequency and leaf size of host plants changed between 2017 and 2019, based on 6,833 records in 0.5-m(2) sample plots. Using turnover data on the butterfly from 2018 to 2019 we modelled local extinction and colonization probabilities. Moreover, we projected future population dynamics with an increasing frequency of extreme years under three different management strategies that regulate the grazing regime.Our results show a substantial decrease in both frequency (46%) and size (20%) of host plants due to the drought, which taken together may constitute a 57% loss of food resources. The butterfly occupancy decreased by over 30% between 2018 and 2019 (from 0.36 to 0.27). The extinction probability increased with increasing 'effective area' of the patch (taking quality reduction due to grazing into account), and the colonization probability increased with increasing connectivity and ground moisture.Projections of future dynamics showed an increasing risk of metapopulation extinction with increasing frequency of years with extreme droughts. The risk, however, clearly differed between management strategies. Less grazing in years with droughts decreased the extinction risk considerably.Synthesis and applications. Extreme weather events can have profound negative impacts on butterflies and their host plants. For the marsh fritillary, an increased frequency of extreme droughts can lead to extinction of the entire metapopulation, even in a large and seemingly viable metapopulation. Increased grazing, due to fodder deficiency in dry years, may lead to cascading negative effects, while active management that reduce grazing in years with droughts can almost completely mitigate these effects.Data are available via the Dryad Digital Repository https://doi.org/10.5061/dryad.s1rn8pk4k (Johansson, Kindvall, Askling, &amp; Franzén, 2020).</p

    Immunogenicity and safety of the tick-borne encephalitis vaccination (2009-2019): A systematic review

    Get PDF
    BACKGROUND Tick-borne encephalitis (TBE) is increasing in Europe. We aimed to evaluate the immunogenicity and safety of TBE-vaccination. METHODS This systematic review was registered at PROSPERO (#CRD42020155737) and conducted in accordance with PRISMA guidelines. We searched CINAHL, Cochrane, Embase, PubMed, and Scopus using specific terms. Original articles, case reports and research abstracts in English, French, German and Italian were included for screening and extracting (JER; PS). RESULTS Of a total of 2464 records, 49 original research publications were evaluated for immunogenicity and safety. TBE-vaccines showed adequate immunogenicity, good safety and interchangeability in adults and children with some differences in long-term protection (Seropositivity in 90.6-100% after primary vaccination; 84.9%-99.4% at 5 year follow up). Primary conventional vaccination schedule (days 0, 28, and 300) demonstrated the best immunogenic results (99-100% of seropositivity). Mixed brand primary vaccination presented adequate safety and immunogenicity with some exceptions. After booster follow-ups, accelerated conventional and rapid vaccination schedules were shown to be comparable in terms of immunogenicity and safety. First booster vaccinations five years after primary vaccination were protective in adults aged 50 years, lower protective antibody titers were found. Allergic individuals showed an adequate response and immunosuppressed individuals a diminished response to TBE-vaccination. CONCLUSIONS The TBE-vaccination is generally safe with rare serious adverse events. Schedules should, if possible, use the same vaccine brand (non-mixed). TBE-vaccines are immunogenic in terms of antibody response but less so when vaccination is started after the age of 50 years. Age at priming is a key factor in the duration of protection
    • 

    corecore